Trial Information

A Phase III, multicentre, international, randomised, parallel group, double blind cardiovascular safety study of BI 10773 (10 mg and 25 mg administered orally once daily) compared to usual care in type 2 diabetes mellitus patients with increased cardiovascular risk.

This study is for patients diagnosed with Type 2 Diabetes Mellitus who have a history of cardiovascular (heart) disease. This trial is being conducted in 40 different countries. There are 20 office visits. The duration of this trial is 3 to 4 years. Subjects will receive a patient stipend between $50 and $75 for each completed visit.

Patient Inclusion Criteria:

Age 18 or older
Diagnosed with Type 2 Diabetes Mellitus
History of myocardial infarction, unstable angina, Multivessel Percutaneous Coronary Intervention (PCI), Multivessel Coronary Artery By-pass Grafting (CABG), ischemic or hemorrhagic stroke or peripheral occlusive arterial disease
HbA1c = 7.0% and = 10.0%
BMI = 45 kg/m2

Patient Exclusion Criteria:

Diagnosed with Type 1 Diabetes Mellitus
Current treatment with systemic steroids
Alcohol or drug abuse within the last 3 months
Medical history of Cancer, except basal cell carcinoma, within the last 5 years

Cheryl Nickles, Patient Recruitment Coordinator
Chase Medical Research, LLC
500 Chase Parkway, 3rd Floor
Waterbury, CT 06708
Phone: (203) 419-4404
Fax: (203) 465-7924
Email: cnickles@chasemr.com

View Map

Research Center Information: Chase Medical Research, LLC

If you would like to learn more about participating in this study, please send an email message using the form below.

Name:
Address:
City:
State:
Country:
Phone:
Email:
Message:

DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.